Remedy Plan Australia

Remedy Plan Australia is the Australian subsidiary of Remedy Plan Therapeutics, a clinical-stage biotechnology company focused on developing a new class of small molecule therapeutics. The company's lead candidate, RPT1G, is a first-in-class hyperbolic NAMPT inhibitor designed to treat various cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), while avoiding the toxicities associated with traditional NAMPT inhibitors. Remedy Plan Australia is currently conducting Phase 1 clinical trials in healthy volunteers to evaluate the safety and pharmacokinetics of RPT1G. The company's proprietary drug screening platform identifies novel compounds that target core vulnerabilities in cancer cells and have potential applications in autoimmune and metabolic diseases. By selectively modulating metabolic pathways, Remedy Plan aims to provide safer and more effective treatments for patients with high-risk malignancies. The Australian entity was established to support the company's global clinical development strategy and leverage local research expertise.